

# **National Deposit Friendly Society Limited**

# **Solvency and Financial Condition Report**

For the financial year ended 31 December 2023

# **Contents**

Summar	/	4
A. Bus	siness and Performance	6
A.1	Business	6
A.2	Underwriting Performance	7
A.3	Investment Performance	7
A.4	Other Information	9
B. Sys	tem of Governance	10
B.1	Governance Structure	10
B.2	Fit and Proper	16
B.3	Risk Management System	17
B.4	Own Risk and Solvency Assessment	18
B.5	Internal Control System	18
B.6	Internal Audit	19
B.7	Actuarial Function	20
B.8	Outsourcing	21
C. Risk Pr	ofile	23
C.1	Underwriting Risk	24
C.2	Market Risk	27
C.3	Credit Risk	29
C.4	Liquidity Risk	30
C.5	Operational Risk	31
C.6	Other Material risks	32
D Val	uation for Solvency Purposes	33
D.1	Assets	33
D.2	Technical Provisions	37
D.3	Other Liabilities	43
D.4	Alternative methods for valuation	44
E Cap	oital Management	45
E.1	Own Funds	45
E.2	Solvency and Capital Requirement and Minimum Capital Requirement	46
E.3	Use of Duration-based Equity Risk Sub-module	47
E.4	Differences between Standard Formula and internal model	47
E.5	Compliance with MCR and SCR	47

APPENDIX		.48
Appendix 1	Quantitative Reporting Templates	.48
Validation		.58

# Summary

Under the UK solvency regime, insurers such as National Deposit Friendly Society Ltd ("National Friendly" or "the Society") are required to publish their annual Solvency and Financial Condition Report ("SFCR"). This is made available through the Society's website and provides information under prescribed headings on the risks faced by the Society, the system of internal controls and governance framework, the financial position and how capital is managed.

#### 2023 overview

Undoubtedly, the environment in which our Society operates has been challenging. Over the past three years, we have witnessed unpredictable events, including conflicts in Europe and the Middle East, interest rate rises, inflationary costs for essentials, and the impacts of COVID-19 alongside the ongoing pressures on the NHS. Despite these challenges, we are proud of how National Friendly has navigated these events.

We have continued to deliver on our strategy amidst significant change, grounded in our mutuality and commitment to creating and protecting value for our members. We are carefully transforming our Society to ensure that we continue to support you, anticipating and adapting to your evolving needs and expectations. This includes enhancing our product offerings, expanding accessibility to family protection to those traditionally underserved by insurers, and fulfilling our responsibilities as a socially responsible organisation within the wider community.

Our success is borne out by key metrics:

- A sustained increase in membership (50,722 in 2023; 42,553 in 2022)
- Growth in Own Funds, a fundamental measure of value creation (£22.7m in 2023; £17.6m in 2022)
- Rising levels of gross written premium income (£31.2m in 2023; £26.1m in 2022)
- Strengthened SCR coverage (148% at YE2023; 142% at YE2022)

Externally, our achievements have been recognised through multiple industry award nominations, reflecting our commitment to excellence in customer service, innovation, and supporting our staff.

While challenges persist, our outlook remains positive. The societal need for the insurance protection we offer, coupled with our mutual structure, free from conflicting shareholder demands, positions us for continued success in serving the best interests of our members, current and future.

# **Financial position**

The table below summarises the Society's capital position under the solvency regime at the end of 2023. The Society applies the Standard Formula for the calculation of its SCR.

Please note, the numbers in the below tables are rounded to the nearest £'000 and match the figures within the relevant QRT templates which are input to the penny. As such, there may be small rounding differences between the individual line items and the totals.

Solvency Balance Sheet (£'000)	2023	2022
Assets	53,084	65,020
Best Estimate Liabilities <sup>1</sup>	23,348	40,888
Other Liabilities	4,095	1,503
Risk Margin	2,966	5,014
Total Liabilities	30,409	47,404
Eligible Own Funds to cover capital requirements	22,675	17,615
Solvency Capital Requirement	15,364	12,408
Excess Own Funds	7,311	5,207
SCR Coverage Ratio	148%	142%

The Society's capital position is assessed in accordance with the PRA Rulebook and the Society manages its business on this basis. This is a risk-based approach to the assessment of capital requirements whereby Technical Provisions are calculated as the sum of the best estimate of liabilities plus a risk margin.

Own Funds are the regulatory measure of the Society's net assets after liabilities, on a solvency basis. It represents the long-term value attributable to its members and allows the Board to establish the impact of management activity over the long term.

The Society's Own Funds have increased by £5.1m during the year, driven mainly by the writing of profitable new business.

The SCR coverage ratio is a measure of how many times the surplus capital covers the SCR. The SCR is the capital that an insurer is required to hold to withstand a set of events covering market, underwriting, counterparty and operational risks such that the resulting level of capital would only be breached during a 1-in-200 year event. The SCR is calculated using the prescribed Standard Formula set out in the regulations. The regulatory requirement is for the SCR coverage ratio to exceed 100%, on top of which the Society has a Solvency Risk Appetite which is set on a Red-Amber-Green scale in order to provide additional security to members.

Over 2023 the Society's SCR coverage ratio increased, from 142% to 148%. This movement was the net impact of a range of underlying factors, the most material of which are set out in section E.1.

-

<sup>&</sup>lt;sup>1</sup> In 2017 the Prudential Regulation Authority ("PRA") approved the Society's application for use of Transitional Measures on Interest Rates ("TMIR"). This allows the Society to continue to use the discount rate from the previous regulatory regime for the existing policies and gradually transition to the current solvency regime over a 16-year period as these policies mature. As at the end of 2023 the amount of TMIR was quantified as being immaterial, therefore zero TMIR has been included as at that date. This was also the case at the end of 2022. Given that neither the current year nor prior year figures include TMIR, we have not shown separate "With TMIR" and "No TMIR" results in this report.

# A. Business and Performance

#### A.1 Business

National Deposit Friendly Society ("the Society") is a mutual friendly society founded in 1868 and incorporated under the Friendly Societies Act 1992.

The Society's registered office and operating address is:

11-12 Queen Square

Bristol

**BS1 4NT** 

The Society's Friendly Society number is 369F.

The Society is authorised by the Prudential Regulation Authority (PRA) and regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (FRN 110008) whose contact details are shown below:

Prudential Regulation Authority	Financial Conduct Authority
Bank of England	12 Endeavour Square
Threadneedle Street	London
London	E20 1JN
EC2R 8AH	

The Society's external auditor is:

**Ernst & Young LLP** 

The Paragon

32 Counterslip

Bristol

BS1 6BX

The Society forms part of a Group which consists of National Deposit Friendly Society Limited and two wholly owned subsidiaries; National Friendly Financial Solutions Limited and National Friendly Software Solutions Limited.

This Solvency and Financial Conduct Report ("SFCR") covers National Deposit Friendly Society Limited on a solo basis as well as the Society plus its wholly owned subsidiaries consolidated on a group basis.

National Deposit Friendly Society Limited is regulated as a solo insurance entity and is the only insurance company within the Group.

The Society writes and administers contracts of insurance as follows:

- With-profits life and pension contracts, including bonds; these are the Society's with-profits business
- Non-profit life contracts; the Society's guaranteed life assurance product
- Non-profit annuity contracts; comprising immediate care plans which fund the provision of long-term care for the balance of the member's life
- Non-profit healthcare contracts; the Society's private medical insurance product
- Non-profit income protection contracts; comprising full and accident only income protection plans
- Unit-linked contracts

All business is written in the United Kingdom.

# A.2 Underwriting Performance

The Society is authorised to write long term insurance business. Premiums received in 2023 comprise regular premiums on existing policies and premiums on new contracts of insurance written in the year.

Reinsurance is used for certain products to limit the overall risk exposure and reduce the volatility of claims, particularly in respect of new healthcare policies. The Society reinsures most of its Private Medical Insurance products with Gen Re and reinsures the Immediate and Deferred Care Plans with Hannover Re. For partially underwritten Guaranteed Life Assurance contracts, the Society has a mass lapse reinsurance treaty in place, with Axis Re. In addition, for MyPMI Level 2 policies, an excess of loss reinsurance treaty is in place.

The Society prepares its financial statements in accordance with UK Accounting Standards including Financial Reporting Standard 102 ("FRS 102"). As such, the underwriting performance detailed in this section is in compliance with FRS 102.

The table below shows the Society's premiums, claims and expenses split by the prescribed lines of business for the period ended 31 December 2023.

			2023			2022
£'000	Health	With-	Unit-	Other	Total	Total
		Profit	Linked	Life		
Gross Premiums	7,870	451	22	22,410	30,753	26,092
Reinsurers' share of premiums	(2,446)	-	-	(5,406)	(7,853)	(5,477)
Gross Claims	(8,564)	(4,460)	(83)	(9,861)	(22,968)	(18,560)
Reinsurers' share of claims	2,699	-	-	5,004	7,703	5,706
Expenses (acquisition & administration)	(3,325)	(953)	(66)	(15,126)	(19,470)	(15,395)

#### A.3 Investment Performance

The Society holds two categories of asset; unit linked, and non-unit linked. The assets held to match the unit-linked liabilities are managed in a separate investment fund which is ear-marked to cover the unit linked liabilities. All non-unit linked assets of the Society are included within the single long-term business fund.

The Society has an Investment & Liquidity Policy which sets out the principles and guidelines for the operation of the Society's investments and liquidity including the framework within which the Society's assets will be invested. This complies with the requirements under the Prudent Person Principle as set out in the PRA Handbook, the Society's risk appetite and the Principles & Practices of Financial Management ("PPFM") relating to with-profits policies. The PPFM outlines broad ranges for asset backing for various liabilities which have been considered in this policy.

The investment strategy of the long-term business fund is to maximise the returns to with-profits policy holders, whilst maintaining adequate solvency and providing adequate liquidity to meet the Society's day to day needs.

As of 31 December 2023, the Society's investment portfolio comprised the following assets:

	20	23	20	22
Type of Assets	Amount (£m)	% of portfolio	Amount (£m)	% of portfolio
Property (other than for own use)	4.3	9.4%	8.5	14.8%
Holdings in related undertakings	0.5	1.1%	0.6	1.0%
Government bonds	26.8	58.6%	35.0	61.0%
Corporate bonds	9.8	21.4%	9.7	16.9%
Collateralised securities	0.0	0.0%	0.5	0.9%
Collective investment undertakings	1.5	3.3%	1.3	2.3%
Deposits other than cash equivalents	1.9	4.2%	1.7	3.0%
Loans and mortgages to individuals	0.9	2.0%	0.1	0.2%
Total	45.7	100.0%	57.4	100.0%

• Note that values above are taken from QRTs and include accrued interest therefore do not reconcile neatly to the financial accounts.

The Society's investment assets are held in government bonds, corporate bonds, equities, commercial property and bank deposits.

In 2023, the total investment asset value decreased from £57.4m to £45.7m, driven on the one hand by the writing of new regular premium business (with bond assets being sold to fund acquisition costs, offset by negative BEL generated on the resulting new business) and by the decision to dispose of two commercial properties (in Norwich and Poole) and largely matched by a corresponding reduction in the value of liabilities.

Investment income:	2023 £'000	2022 £'000
Income from land and buildings	1,033	624
Fixed interest stocks	2,004	1,338
Ordinary shares	27	40

Investment income:	2023 £'000	2022 £'000
Income from listed investments:	2,031	1,378
Bank interest	158	27
Mortgages	2	2
Income from other investments:	160	29
Income from investments	3,224	2,031
Net losses on realisation of land and buildings	(84)	(17)
Net losses on realisation of listed investments at fair value through profit and loss	(689)	(11,367)
Net gains/(losses) on realisation of investments	(773)	(11,384)
Investment income/(loss)	2,451	(9,353)
Net unrealised gains/(losses) on investments		
<ul> <li>Land and buildings</li> </ul>	853	(660)
<ul> <li>Listed investments at fair value through profit and loss</li> </ul>	7,164	(9,729)
<ul> <li>Assets held to cover linked liabilities at fair value through profit and loss</li> </ul>	136	(244)
	8,153	(10,633)
Total investment return	10,604	(19,986)
Investment Expenses		
Investment management expenses	182	222
Investment property direct costs	314	455
	496	677

# A.4 Other Information

The Society has no other material information regarding its business and performance to report.

# **B. System of Governance**

#### **B.1** Governance Structure

#### **Board of Directors**

The Society's Board of Directors has responsibility for the oversight of the Society's business and sets its strategy and risk appetite. The Board has established a number of Board delegated Committees to oversee certain key functions under its overarching authority, reporting their activities and making recommendations to the Board. Each committee is chaired by a Non-Executive Director. All Non-Executive Directors are considered to have appropriate skills and expertise to undertake their role within the Board and Committees. All Non-Executive Directors are members of all Board delegated Committees.

The Board is the main decision making body for the Society. It determines the strategic direction and has responsibility for the overall management of the Society's business affairs. The Board sets the Society's values and standards and has overall responsibility for ensuring that obligations to members and other stakeholders are met.

The Board monitors and oversees the Society's operations with the purpose of maintaining competent management, sound planning, robust and prudent risk and capital management, an effective internal control environment, a culture of risk awareness and ethical behaviour and compliance with statutory and regulatory obligations.

The Board consists of such number of individuals as the Board may determine from time to time but no more than 50% shall be Executive Directors. As at 31 December 2023, the Board comprised four Non-Executive Directors and two Executive Directors:

- Geoff Brown (Chairman & Non-Executive Director)
- Mark Searles (Senior Independent Non-Executive Director)
- Simon Thomas (Non-Executive Director)
- Victoria Wentworth (Non-Executive Director)
- Graham Singleton (Executive Director)
- Julian Ellacott (Executive Director)

Ratification of the appointment of Simon Thomas and Victoria Wentworth will be sought and obtained at the Society AGM in 2024.

#### **Audit Committee**

The role of the Audit Committee is to consider and assist the Board in fulfilling its oversight responsibilities with regards to the integrity and effectiveness of the systems of internal control, financial processes, financial statements and performance of the internal audit function. The Audit Committee and Risk and Compliance Committee work together effectively to cover all relevant issues and ensure that any pertinent areas of overlap are appropriately addressed.

Members of the Audit Committee are appointed by the Board and comprise all Non-Executive Directors. Throughout 2023, the Chair of the Board was a member of the Audit Committee. Whilst this is not in compliance with the AFM Governance Code, the Board decided that it was important for the Audit Committee to benefit from the Chair's experience of the Society and his actuarial skills and qualifications. Membership of all Board Committees is reviewed at least annually and the Chair's ongoing membership of the Audit Committee will be reviewed again in 2024.

The primary responsibilities of the Audit Committee are to:

- Review the Society's financial statements and critical accounting policies, judgements and estimates including the assumptions to be used in respect of morbidity, mortality, persistency and expenses.
- Oversee the annual external audit of the financial statements, considering the planning, scope and findings of the external auditor.
- Provide advice to the Board on whether the Annual Report and Accounts, taken as a whole, are fair, balanced and comprehensible and provide the information necessary for members to understand the Society's position and prospects, including performance, business model and strategy.
- Review the adequacy and effectiveness of the Society's internal financial controls and internal
  control and risk management systems in conjunction with reviewing reports produced by the
  Society's internal and external auditors.
- Review and monitor the independence of the external auditors, in particular the appropriateness of the provision of non-audit services.
- Consider the appointment, performance and remuneration of the external and internal auditors.

#### **Risk and Compliance Committee**

The Risk and Compliance Committee assists the Board in its leadership and oversight of risk. This includes the understanding and, where appropriate, optimisation of current and future risk strategy, overall risk appetite and tolerance, risk management including risk policies, process and controls and the promotion of a risk awareness culture throughout the Society. It is also responsible for the oversight of regulatory compliance including conduct risk and the policies and procedures within the Society.

The Committee consists of all Non-Executive and Executive Directors.

The primary responsibilities of the Risk and Compliance Committee are to:

- Review, monitor and challenge the Society's risk management framework, including the capability to identify, mitigate and manage emerging and new risks in conjunction with the Audit Committee.
- Oversee the Society's ongoing compliance with statutory and regulatory requirements and ability to identify emerging regulatory trends.
- Review and oversight of strategic risks when there is significant change to the Society's strategic business plan.
- Oversee and provide input and challenge to the production of the Society's Own Risk Solvency Assessment and related stress tests and make recommendations.

- Make recommendations concerning the Society's overall risk appetite, tolerances and strategy.
- Review any material breaches of risk appetite and risk tolerance together with the adequacy and implementation of proposed actions, ensuring that all matters are reported appropriately to the Board.
- Monitor and review the Society's management of the risks of climate change.
- Review, update and test operational resilience, including the Society's business continuity plans on a regular basis.
- Review the Society's procedures for the prevention and detection of bribery and corruption;
   oversee anti-money laundering and financial crime systems and controls.

#### **Investment Committee**

The Investment Committee monitors compliance with the terms of the PPFM and Investment & Liquidity Policy in relation to the management of the Society's investments and with consideration of the needs of both with-profit and non with-profit policyholders.

The Committee consists of all Non-Executive and Executive Directors.

The primary responsibilities of the Investment Committee are to:

- Set the Investment & Liquidity Policy, subject to Board approval, in compliance with the terms
  of the PPFM in respect of with-profit policyholders and in line with the requirements of other
  non with-profit policyholders.
- Oversee the application of the Investment & Liquidity Policy.
- Periodically review the Investment & Liquidity Policy, in particular in respect of capital requirements, overall market conditions and environmental, social and governance considerations.
- Develop and keep under review the appropriateness of key risk indicators and tolerances and information provided by third parties such as financial institutions, asset managers and rating agencies.
- Appoint and monitor the performance of the Society's external investment and property managers, and custodian.

# **With-Profits Advisory Arrangement**

The role of the With-Profits Advisory Arrangement ("WPAA") is to objectively monitor and provide independent judgment on the extent to which procedures, systems and controls are adequate and effective to enable the Society to comply with the requirements of the FCA Handbook regarding the management and governance of with-profits business.

The WPAA comprises all Non-Executive Directors. The With-Profits Actuary attends meetings as appropriate.

No member of the WPAA holds an Executive position within the Society, nor has acted as a professional advisor to the Society within the year preceding a proposed first appointment to the WPAA.

The primary responsibilities of the WPAA are:

• In advising and reporting to the Board, the WPAA monitors and considers all relevant issues, including but not limited to:

- a) The rights, interests or expectations of different classes and generations of with-profits policyholders.
- b) The manner in which the Society exercises discretion in the conduct of the with-profits business.
- c) The manner in which the Society addresses competing or conflicting rights, interests or expectations of its policyholders (or groups of policyholders).
- d) Proposals from the With-Profits Actuary for bonus rates, surrender values or market value adjustments in respect of with-profits policies.
- e) Proposals for changes to the PPFM.
- f) Compliance with the PPFM.
- To make an annual report to with-profits policyholders, recording any significant activity it has undertaken and highlighting any issues that it has raised with the Board.

#### **Nomination Committee**

The Nomination Committee reviews the structure, size and composition of the Board and makes recommendations to the Board with regard to any adjustments that are deemed necessary. The Committee comprises all Non-Executive Directors, plus the Chief Executive Officer.

The primary responsibilities of the Nomination Committee are to:

- Review the structure, size and composition of the Board including the balance of skills, experience and diversity and make recommendations to the Board with regard to any changes.
- Review the succession plans and leadership needs of the Society, both Executive and Non-Executive, giving consideration to current and future business needs and requirements, and the continued ability of the Society to compete effectively in the marketplace.
- Be responsible for identifying and nominating for the approval of the Board, candidates to fill
  vacant Board positions as and when they arise.

# **Remuneration Committee**

The underlying purpose of the Remuneration Committee is to oversee the Society's remuneration policy.

The Committee comprises all Non-Executive Directors. The Chief Executive attends meetings as appropriate.

The primary responsibilities of the Remuneration Committee are to:

- Establish, implement and maintain the remuneration policy and practices in line with the Society's risk management strategy, risk profile and objectives.
- Observe industry standards for corporate governance regarding Executive Director, Non-Executive Director, and Senior Management Function's remuneration, including disclosure requirements and avoidance of conflict between business objectives and compliance with legal and regulatory requirements.

#### **Executive Committee**

The Executive Committee forms part of the Society's corporate governance structure. The Board is the main decision making body and the Executive Committee is charged (via delegation from the Chief Executive) with the operational running of the Society's business.

The Committee consists of the Executive Directors and all members of the Executive that are in place to support the Chief Executive Officer.

The primary responsibilities of the Executive Committee are to:

- Determine the Society's strategic positioning, mission, aims and priorities, as part of the Society's strategic and operational business plans for consideration by the Board.
- Implement agreed strategy including strategic projects, and report to the Board on their return on investment and performance against delivery time and budget.
- Manage the business on an ongoing basis, reviewing performance against budget and business Key Performance Indicators (KPIs) as agreed with the Board. Ensure appropriate and accurate management information is provided to management and the Board.
- Design and implement a framework of processes and controls, as agreed with the Board, that
  is effective in allowing the business to run efficiently, in compliance with the Society's Risk
  Appetite Statement, legislation and regulation and enables the effective management of the
  Society's capital, risks and ORSA. Risk KPIs plus risk and control ratings are reviewed regularly
- Establishing systems for business relationships/partnerships, particularly outsourced arrangements, so that regulatory obligations are complied with, in compliance with the Outsourcing policy, contractual service standards are delivered and business needs met.
- Oversee the strategic approach to regulatory and legislative matters, including new legislation and regulations.
- Implement and maintain an effective member relations strategy.
- Determine the Society's internal culture and values, ensuring alignment with the Board's cultural objectives, ensuring they are embedded, maintained and promote a culture of risk awareness and ethical behaviour for the Society's staff to follow in pursuit of its business goals and which is conducive to treating customers fairly and good customer outcomes.
- Undertake tasks delegated by the Board as required.

The Society monitors its system of governance on an ongoing basis and considers it to be appropriate for the Society, taking into account the nature, scale and complexity of the risks inherent in the business.

No material changes in the system of governance have taken place during the reporting period.

#### **Remuneration Policy**

The Society's approach to remuneration is an integral part of its business strategy and the policy is designed to attract, retain and motivate competent, experienced and skilled staff. The policy is based on the following principles:

- a) Reward and remuneration will be clear and competitive within the market so that individuals are motivated and the Society is able to attract and retain key talent.
- b) Remuneration will be determined fairly and objectively across the Society.
- c) Variable reward for the Directors and key function holders will be linked to strategic personal objectives.

- d) Total remuneration will comprise a fixed base salary as well as a variable discretionary bonus and other financial and non-financial employee benefits.
- e) The remuneration policy will be transparent and accessible to all Society staff.

The fixed and variable components of remuneration for Executive Directors and persons responsible for key functions within the Society are broken down as follows:

#### Base salary

Base pay will normally be reviewed annually in April. Pay rises are not guaranteed, but the review will take into consideration any increase in cost of living and, where appropriate other external market factors, in line with the approach taken for all employees.

Pay reviews may take place at other times of the year to reflect a change in role and/or significant change in responsibilities. The Committee may consult with external advisors as appropriate for such pay reviews, who can undertake a job evaluation to provide a guide salary range relevant to the role. The evaluation considers the demands of the role and then applying factors derived from salary research data, takes account of the Society's size, sector and location.

#### Performance Related Pay

The Executive Directors and members of the Executive Committee are eligible for annual Performance Related Pay. This comprises two component parts; a short term incentive plan with a maximum potential cash bonus of 60% of base salary (100% for the Chief Executive), 30% of which is deferred, payable in April 2026. Performance is assessed on a collective basis against corporate objectives identified within the Society's balanced score card and delivery of personal objectives.

#### **LTIP**

Whilst there is a deferred component to the performance related pay, there is currently no formal Long Term Incentive Plan ("LTIP") scheme in operation. The Remuneration Committee is seeking to introduce this in 2024, considering the Society's medium and long term objectives over an extended time horizon, whilst taking account of the Society's risk profile.

### Retirement and Related Benefits

The Executive Directors are members of a defined contribution pension scheme which is available to all employees. The Society contributes up to a maximum of 12% of base salary per Director, dependent upon personal contribution levels and consistent with the contribution levels for all staff. The Chief Executive receives an allowance in lieu of a contribution to a defined contribution pension scheme, the cost to the Society is the same as a 12% contribution to a pension scheme.

#### Other Benefits

Executive Directors are entitled to death in service benefit of four times basic salary and a company car or car cash allowance. Other benefits available to all staff are also available to Executive Directors such as private medical insurance, salary sacrifice schemes for pension contributions and the cycle to work initiatives and for season ticket loans.

#### Non-Executive Directors

All Non-Executive Directors including the Chair have letters of appointment which set out their duties and responsibilities. The appointment of Non-Executive Directors is usually for a period of three years and is subject to election and re-election at the Society's AGM. After nine years of service or when a director reaches the age of 70, re-election becomes an annual process.

Fees are benchmarked against similar roles in comparable organisations. Fees are calculated on an annual rather than a daily basis. However, it is assumed that to fulfil the basic role of a Non-Executive Director, sufficient time and commitment is required each month for review work and attendance at regular Board meetings, the Society's AGM, Special General Meetings where appropriate, other ad hoc meetings with regulators and advisers as may be required and training courses.

Non-Executive Directors' remuneration is not performance related nor pensionable and Non-Executive Directors do not participate in any incentive plans. However, a formal bi-annual appraisal process is undertaken where the views of all Directors are taken into consideration and the outcome of this is ratified by the Board.

Fees for Non-Executive Directors are determined by the Executive Directors and subject to approval of the Board as a whole. They are designed to recognise the responsibilities of Non-Executive Directors and to attract individuals with the necessary skills and experience to contribute to the objectives of the Society.

## **B.2** Fit and Proper

#### Skills, knowledge, and expertise

The Society ensures that persons who effectively run the business or hold responsibility for key functions (defined as "Senior Managers") have, individually and collectively, an appropriate depth and diversity of knowledge, skills, qualifications, and experience relevant to their respective roles and duties, in order to manage and oversee the running of the organisation in an effective, compliant, and professional manner.

These functions lie within the financial regulators' Senior Managers and Certification Regime ("SM&CR") that designates a number of defined senior management function ("SMF") roles and are subject to additional conduct standards. The SMF roles are subject to regulatory approval prior to appointment to their new role and undergo regular assessment of fitness and propriety.

# **Fitness and Propriety**

To ensure that Senior Managers are fit and proper, they are recruited giving due regard to honesty, integrity and reputation, competence, and capability of the candidate, as well as their fitness and propriety. This is covered in the FCA FIT rules and a process is in place to ensure that all candidates in this category are reviewed against the regulatory requirements.

Certification individuals are identified as a key person that could cause customers or the business significant harm if they failed to perform their role effectively. These are subject to the same fitness and propriety expectations as Senior Managers.

On an annual basis, the Society will carry out an assessment to certify that both categories (SMF and certified individuals) are fit and proper to carry out their function in the business.

The Society has a 'Fit and Proper' policy including an annual Fit and Proper declaration.

#### **B.3** Risk Management System

#### **Risk Management System**

The Society's risk management framework seeks to ensure that there is an effective process in place to manage risks across the Society. Risk management is integral to all aspects of the Society's activities and is the responsibility of all staff. Senior managers have a particular responsibility to evaluate their risk environment, to put in place appropriate controls and to monitor the effectiveness of those controls. The risk management culture emphasises careful analysis and management of risk in all business processes. Risks are identified, assessed, and managed at a strategic, operational, conduct, and financial level.

The framework comprises the stated risk appetite and tolerance for strategic, operational, and financial risks and associated risk registers. The Society has a number of specific risk metrics which assist management in assessing whether outcomes are consistent with the Society's risk appetite.

The governance of risk management is aligned to the three lines of defence:

- The first line of defence comprises the operational business areas who are responsible for the ongoing assessment of risk and performance of day to day controls.
- The second line of defence is represented by internal assurance (oversight and monitoring) of the operational business areas provided by Compliance and Risk.
- The third line of defence represents independent assurance on the effectiveness of the Society's systems and internal controls, and is provided by the internal audit function and other skilled external practitioners e.g. consulting actuaries.

The Board has the ultimate responsibility for setting the Society's strategy for risk management; reviewing the Society's systems of risk management and internal control and their effectiveness and being responsible to the regulator and its policyholders for ensuring compliance with regulatory obligations including capital and solvency requirements of the ORSA.

The Board determines the risk appetite, taking into consideration recommendations from the Risk and Compliance Committee and senior management. The Risk and Compliance Committee reviews the Society's risk appetite statements at least annually before submission to the Board for approval.

# **Risk Management Function**

The Risk function is led by the Head of Risk and Strategic Projects. Key responsibilities of the function include:

- Maintenance, development, and monitoring of the risk management framework.
- Leading the review of all risks within the Society's Risk Universe on a quarterly basis to reflect any changes including the identification of emerging risks.

- Provision of regular risk reporting to the Risk and Compliance Committee including dashboard reporting of the current risk assessment versus appetite.
- Undertaking second line monitoring to assess the operational effectiveness of the first line of defence.
- Leading the review of the Society's risk appetite on at least an annual basis taking into account the Society's business plan and strategic objectives.

To ensure independence of this function, it has a direct reporting line to the Risk & Compliance Committee with access to the Committee Chair.

#### B.4 Own Risk and Solvency Assessment

The ORSA process and report enable the Board to assess the risk-based capital requirement of the Society based upon its strategic business plan. The Board is ultimately responsible for the review, challenge and approval of the ORSA framework, ORSA Policy and Process approval and the ORSA report.

A five year base case projection of the Solvency II Balance Sheet and Solvency Coverage Ratio ("SCR") position is produced incorporating a number of key assumptions about the anticipated level of new business, economic and demographic risks plus insurance risks including morbidity, lapse and future expense assumptions. This projection is subjected to a range of stress tests in robust upward and downward scenarios including stresses for lower than expected new product sales, worsening morbidity plus lapses and expenses exceeding the levels assumed.

The Society's ORSA process operates continuously through the course of the year, accompanied by periodic formal reporting. The full ORSA report is produced and approved by the Board at least annually. Business performance key metrics are tracked versus the ORSA target on a monthly and quarterly basis through management reporting. Additionally, the ORSA will be reperformed at intermediate times if capital adequacy is impacted either through capital erosion from a material event or a material change in the risk profile. Circumstances that will trigger the need for an ORSA outside the regular timescales have been agreed and documented within the ORSA Policy.

The Society has determined that the Standard Formula is appropriate to calculate the required solvency capital and to assess overall solvency needs.

# **B.5** Internal Control System

The Society has established an internal control framework encompassing key controls of the business, both financial and non-financial. The effectiveness of these controls are regularly reviewed by the Executive Committee, the Board and its appointed Committees.

Key controls include:

• Strategic business planning and budgeting processes – defining the business objectives and key initiatives, aligned to the assumptions within the ORSA projections and the Society's risk appetite. Performance against these objectives is monitored throughout the year by the Board and Executive Management.

- **Risk appetite process** performed at least annually in line with the business planning process and sets the detailed risk appetite for the key risk areas within the Society.
- **Authority and approval limits** clearly documented throughout the Society such as underwriting guidelines, claims payment authorities, invoice approval and bank transfers.
- **Investment controls** have been developed and documented within the Investment Policy detailing the investment principles and strategy and defining investment parameters, policies, controls and valuation methodologies.
- Data validation and reconciliation processes detailed data quality control procedures are
  in place across the Society, including cross checking and reconciliations between different
  sources to validate that the data within our systems and used for reporting is accurate and
  complete.

The financial statements are subject to internal controls in their production and review and undergo external audit review and Board approval prior to publication. The actuarial methodology and assumptions follow actuarial practices and standards and are subject to review and approval by the Board.

The internal control system is subject to periodic internal audit reviews of the appropriateness and effectiveness of the controls. These are subsequently presented to and challenged by the Audit Committee

#### **Compliance Function**

The overall responsibility for overseeing the compliance of the Society and advising and supporting the business on regulatory compliance matters is a key function and approved by the regulators as a senior management function (SMF 16 Compliance Oversight).

This function is held by the Head of Legal and Compliance who is deemed to be an appropriately competent person and responsible for ensuring the effectiveness of Society's systems and controls to meet regulatory compliance requirements and undertake compliance reporting to the regulators.

The Compliance function is an independent control function with formal status within the overall governance framework. It is not engaged in areas of the business which could create a conflict of interest and is responsible for reporting to executive management and the Board any breaches or non-compliance with relevant policies, rules, and regulations.

The function has access to all information necessary to carry out its responsibilities.

# **B.6** Internal Audit

During 2023, the Internal Audit function was established as an in-house function. The Head of Internal Audit holds qualifications with both the Chartered Institute of Internal Auditors and the Chartered Management Institute. Internal Audit reports administratively to the Chief Executive Officer and to maintain the independence of internal audit activities they report functionally to the Audit

Committee. The Chair of the Audit Committee is responsible for overseeing the independence and performance of the internal audit function.

On an annual basis the Internal Audit function formulates and presents an annual audit plan to the Audit Committee for approval. The internal audit plan is risk based and appropriate to the nature, scale and risks of the Society. The plan is developed to make sure that all areas within the business are subject to a regular review. The plan is flexible so that changes can be made during the year as a result of changes in priorities, external conditions and risk areas.

Based on the audit plan, the internal audit function assesses the adequacy and effectiveness of controls covering areas of governance, operations and information systems.

#### **B.7** Actuarial Function

Since September 2021 the Chief Actuary position has been held by Executive Director, Julian Ellacott, who is a Fellow of the Institute and Faculty of Actuaries, holds the appropriate Practising Certificate and has complied continuously with the specific professional obligations this requires.

The Chief Actuary is supported by an internal team including at least one qualified actuary, and external peer review of key pieces of work is also obtained. The Chief Actuary is the management function holder approved by the regulators under the SMR.

The key responsibilities of the Chief Actuary role are:

- Providing actuarial advice to the Society's senior management and Board.
- Regulatory reporting of technical provisions and capital requirements.
- Contributing to the effective risk management system through modelling of risks and actuarial forecasts which form part of the ORSA process.
- Ensuring the effectiveness of the Society's actuarial methodology, assumptions, systems and controls.
- Providing actuarial opinion on data quality, underwriting and reinsurance effectiveness.

The Actuarial function is established as an independent control function within the overall governance framework.

The role of With-Profits Actuary is a separate independent function which is outsourced to Sally Butters of OAC Ltd. The With-Profits Actuary reports to the Board through the WPAA and has the following key responsibilities:

- Advising on key aspects of the discretion to be exercised with regards the Society's withprofits insurance business.
- Advising whether the assumptions used to calculate the future discretionary benefits within
  the technical provisions are consistent with the Society's PPFM in respect of the with-profits
  insurance business.

# **B.8** Outsourcing

The Society works with a number of third party suppliers who provide a range of goods and services. Engagement of these suppliers is governed by the Society's Outsourcing and Purchasing Policies. Service quality is monitored through an ongoing review of service level agreements with each third party.

The Outsourcing Policy sets out the following requirements:

- Third party due diligence includes an assessment of key risks and material factors which could affect the potential service provider's ability to perform the required business activity. Checks including financial, regulatory, conflicts of interest, information security, operational resilience and business continuity are undertaken.
- All outsourcing arrangements must be established with a written contractual agreement which requires internal approval as set out in the policy. Where a critical function is outsourced, this requires Board approval.
- A record of all material outsourced arrangements is maintained with a process for regular monitoring by the person responsible for the outsourced activity, overseen by the Risk function.

During the period, critical or important services were outsourced to the following organisations;

Provider	Service outsourced	Jurisdiction
OAC Ltd	With-profits Actuary Mo.net actuarial system development	UK
Software Alliance Ltd	Mo.net actuarial system support	UK
Medicals Direct Group	Specialist medical screening	UK
Alliance Surgical Plc <sup>1</sup>	Medical insurance claims administration	UK
Healix Health Services <sup>1</sup>	Medical insurance claims administration	UK
XPS Pensions Group	Pension policy administration	UK
Link Group	Unit linked policy administration	UK
Fidelity International <sup>2</sup>	Investment Managers - fixed income & equities	US
Royal London Asset Management <sup>2</sup>	Investment Managers - fixed income & equities	UK
Church House Investments Ltd	Investment Managers – unit-linked fund	UK
Mellersh & Harding LLP	Property management and surveyors	UK

Provider	Service outsourced	Jurisdiction
Northern Trust Corporation	Investment custodians	US
PwC <sup>3</sup>	Internal audit	UK
Morrison Govan LLP	Taxation services and advice	UK
Brightcloud Technologies Ltd	Hosted IT infrastructure services	UK
Spark Data Systems Ltd	Policy administration system support, development and data migration	UK

<sup>&</sup>lt;sup>1</sup>The outsourced provision of medical insurance claims management transitioned from Alliance Health Group to Healix Health Services in Q3 2023.

<sup>&</sup>lt;sup>2</sup>Following a competitive tender process, Royal London Asset Management were appointed to succeed Fidelity as the Society's Investment Manager in 2023.

<sup>&</sup>lt;sup>3</sup>The Internal Audit function was insourced in March 2023 with the appointment of an in-house Internal Audit Manager.

#### C. Risk Profile

#### **Risk Assessment Process**

Risk management is an integral part of the Society's business activities through the identification of key threats to business strategy. Mitigation plans are put in place to ensure the Society remains sustainable and continues to operate in the best interests of its policyholders.

The extent to which the Society tolerates risk is described by performance indicators, operational parameters and process controls set out in the Risk Appetite Statement.

The Society's risk appetite determines the level of risk the Society is prepared to accept as well as the action and mitigation to be implemented against identified risks. Risks are rated based upon impact and probability and it has been determined that any risk with a 'Very High' residual risk rating will require an action plan stating what action is to be taken and on what timescale.

#### **Concentrations**

The Society has a well-diversified portfolio of assets with a defined Investment & Liquidity Policy limiting exposure to any one asset class. Therefore, it is not subject to material concentration risk in respect of its asset holdings.

#### **Risk Profile**

The Society's risk profile depends on the nature of the insurance policies issued as at 31 December 2023, the assets held to match the liabilities and Own Funds and the Society's defined benefit pension scheme arrangement, which also contributes to the overall SCR calculation.

The Society faces a number of material risks, which are summarised below and detailed in sections C1–C5. As at 31 December 2023 the Society had over 52,000 in force long-term policies (compared to approximately 42,000 as at 31 December 2022). The relative proportions of policy numbers and Best Estimate Liabilities ("BEL") are as follows:

Product Group	Policies	BEL (£m)	Policies %	BEL %
With profits contracts	4,736	26.4	9%	113%
Other life contracts	36,222	- 16.7	68%	-71%
Health similar to life contracts	11,932	12.3	23%	53%
Unit linked contracts	68	1.4	0%	6%
Total	52,958	23.3	100%	100%

The high number of "Other life contracts" which give rise to net negative BEL is driven by:

- The Society has Death Benefit Only contracts with low sums assured. These account for 7% of the total policies by number, but only 1% of the BEL.
- The Society has just over 30,000 Guaranteed Life Assurance ("GLA/GLAP") policies, which in aggregate have negative BEL.

Given the wide range of inforce contracts, the Society has some exposure to each of the core underwriting risks. These are summarised in the table below. However, there are no material concentrations, as shown in the tables under section C.1.

Contract Type	Mortality	Longevity	Morbidity	Lapse	Expense
With-profits contracts	Υ	Υ			Υ
Other life contracts	Υ	Υ		Υ	Υ
Health similar to life contracts		Υ	Υ	Υ	Υ
Unit linked contracts					Y

#### Overall risk exposure

The Society uses the Standard Formula approach to quantify its exposure to risk. The table below shows the composition of the undiversified net SCR by each of the main risk categories for the current and previous year (ie there is no allowance here for diversification in this comparison).

Risk	2023 (£m)	2022 (£m)	2023	2022
Market Risk	3.6	5.0	14%	24%
Counterparty Risk	0.6	0.7	2%	3%
Underwriting Risk (Life)	17.2	10.9	67%	52%
Underwriting Risk (Health SLT)	2.9	3.3	11%	16%
Operational Risk	1.3	1.0	5%	5%
Total	25.6	20.8	100%	100%

The most significant risks faced by the Society are market and underwriting risks.

# C.1 Underwriting Risk

Underwriting risk arises when premiums and investment income are insufficient to pay the contractual benefits on a policy or when the actual demographic experience and/or expenses of administering a group of policies is worse than assumed in the calculation of the BEL.

In accordance with the Standard Formula, the Society has assessed the Basic SCR ("BSCR") for underwriting risk separately for Life and Health Similar to Life Techniques ("SLT") business. (There are a small number of contracts that have both health and life assurance benefits. The majority of risk arises from the health benefits and they have therefore, been classified as Health Similar to Life Techniques.) The table below compares the capital requirements comprising the BSCR as at 31 December 2023 by key risk.

	Life	Health		
SCR	Underwriting	Underwriting	Total £m	
	Risk (£m)	Risk (£m)		
Mortality	5.4	0.0	5.4	
Longevity	1.0	0.0	1.1	
Morbidity	0.0	1.1	1.1	
Lapse	8.8	1.2	10.0	
Expenses	1.6	0.5	2.1	
Pandemic	0.4	0.0	0.4	
Total	17.2	2.9	20.1	

#### **Mortality Risk**

Where insurance contracts pay out a lump sum on death, the Society is exposed to the risk that policyholders die, on average, sooner than expected. The key exposure to mortality risk is under the GLA/GLAP contracts. There are two variants of this contract with differing underwriting requirements. At 31 December 2023, they accounted for 58% of the in force book (by policy count) (2022: 48%).

Mortality risk is an increasing risk for the Society because of increased sales of its GLAP product.

There is also the risk of a concentration of deaths due to a particular type of catastrophe, for example a pandemic; however concentrations of risk was not evident as a result of the COVID pandemic. They could arise from other types of pandemic, or other phenomena, but overall this is not currently a material risk for the Society.

#### **Longevity Risk**

Where insurance contracts pay out benefits that are dependent on survival or which lead to higher claims costs with increased longevity, the Society is exposed to the risk that policyholders die, on average, later than expected. The key exposures to longevity risk are non-profit annuities in payment, with-profits retirement annuity contracts which have a guaranteed annuity option and healthcare policies. Longevity risk on the care annuity policy is substantially reinsured, therefore there is little residual exposure on the part of the Society.

#### **Morbidity Risk**

The Society's income protection and health insurance contracts are exposed to morbidity risk, the risk that claims payments for medical or health benefits are higher than expected. Higher claims may occur due to higher numbers of claims and/or larger claim amounts than expected. The most significant risk applies to the whole of life healthcare policies, where premiums cannot be reviewed to offset the impact.

There is also the risk of additional claims arising from a catastrophe of some sort. The level of this risk is hard to gauge; as an example the COVID pandemic has had an impact on the Society's morbidity claims, but in the short term at least the impact was to reduce claims rather than increase them, with a later "bounce back" of claims.

#### **Lapse Risk**

This is the risk that a policyholder lapses or surrenders their policy before the planned maturity date resulting in a loss to the Society. For some contracts, higher lapses than expected can result in a loss if lapses occur before the Society has recouped its acquisition costs or if the surrender benefit exceeds the policy reserve. Lower than expected lapses can lead to a loss when the expected value of future claims and administration expenses exceeds the expected value of future premiums.

Overall, a mass lapse scenario leads to the greatest loss in Own Funds when compared to a permanent increase or decrease in lapses. Mass lapse also leads to a loss in Own Funds for reviewable premium Healthcare policies and for the new health, GLA/GLAP and income protection products that the Society has launched in recent years. During 2022 the Society executed a reinsurance arrangement to mitigate the impact of a mass lapse event on the GLAP product.

## **Expense Risk**

The Society is exposed to the risk that future expenses are higher than expected and that the amounts reserved need to be increased to reflect a higher expense assumption. This can arise through a one-off shock to certain expenses and/or higher than expected expense inflation, both resulting in an increase of liabilities.

#### Assessment and risk mitigation techniques

The Society has processes in place to reduce and monitor each of the underwriting risks:

- The risk register covers the key underwriting risks and is reviewed quarterly with a summary reported to the Risk and Compliance Committee on a quarterly basis.
- Reinsurance reduces exposure to large claims and higher than expected claim frequency.
- Regular monitoring of demographic assumptions versus actual experience to aid early identification of adverse trends.
- New product design reduces risk by using reinsurance (where appropriate) and offering reviewable premiums rather than guaranteed.
- Underwriting at point of sale minimises the risk of adverse selection.
- Appropriate claims processes, to ensure the validity of claims before making payment.
- Expenses are closely monitored and combined with organisational restructuring, where necessary, to ensure the right cost base.

A full valuation of the technical provisions and life obligations SCR is performed on a quarterly basis, and estimates of the solvency position are produced for intervening months ends. The SCR coverage is reported to the Society's Board as part of the monthly MI pack.

#### Risk sensitivity for underwriting risks

The Society assesses underwriting risk by considering a number of stand-alone stress tests and scenarios affecting material demographic and expense assumptions in its ORSA. The analyses consider the impact of an immediate shock to the starting balance sheet in addition to the impact on its forward-looking assessment of the future balance sheet position.

A series of stand-alone stress tests have been performed on the Society's insurance assets and liabilities as at 31 December 2023 as part of the Standard Formula calculation of the SCR. The most onerous of the underwriting sensitivities identified is a 40% mass lapse scenario.

#### C.2 Market Risk

This represents the risk that the Society's solvency coverage is adversely affected by changes to financial market conditions, which impact the fair value of assets held. The Society has a portfolio of UK and overseas assets comprising equity, property, fixed interest and money market assets.

#### **Material market risks**

The following table shows the split of total assets between different asset types, which determine the nature and magnitude of the market risks:

Insurance Asset Mix	Value (£m)
Equity	3.2
Property	7.0
Government Bonds	26.7
Corporate Bonds	9.7
Cash	6.3
Other Assets	0.2
Total	53.1

The following table shows the relative size of the undiversified net SCR and elements of the Standard Formula market risk module in respect of each asset class holding. The SCR allows for market risk in respect of the assets held by the Society's defined benefit staff pension scheme. The staff defined benefit pension scheme contributes 27% of the undiversified net SCR in respect of market risk.

SCR Market Risk	Insurance (£m)	Pension Scheme (£m)	Total (£m)	% of total market risk
Interest Rates	1.5	0.1	1.5	43%
Equity	0.4	0.0	0.4	12%
Property	0.4	0.0	0.4	12%
Credit Spread	0.3	0.8	1.1	30%
Currency	0.0	0.0	0.0	1%
Concentration	0.0	0.1	0.1	2%
Total	2.7	1.0	3.6	100%

The most significant components of market risk at 31 December 2022 are interest rates and credit spreads, accounting for 43% and 30% of the undiversified market SCR respectively. Property risk, which arises mainly from exposure to property backing the with-profits liabilities where the guaranteed policy values are now biting or where there is surplus property, in excess of the allocation to liabilities, has reduced in significance over the past year, as a result of the sale of two properties, leaving only three properties remaining.

#### **Interest Rate Risk**

Interest rate risk arises when a fluctuation in interest rates adversely affects the Society's SCR coverage and can arise when the value of assets and liabilities do not move in line with each other when interest rates change. Both an increase and a decrease in interest rates are tested and the SCR is based on the more onerous reduction in interest rate scenario. The interest rate increase stress is the more onerous on the combined position of both insurance business and pension scheme.

#### **Equity Risk**

The Society is exposed to the risk that the market value of its equity assets falls without a corresponding reduction in its liabilities, leading to a loss in SCR coverage.

Equity assets are held to provide real returns to with-profits life and unit-linked contracts. The loss absorbing capacity of with-profits and unit-linked contracts mitigates a significant proportion of the equity risk in the insurance business.

# **Property Risk**

The Society is exposed to the risk that the market value of its property assets falls without a corresponding reduction in its liabilities leading to a loss in SCR coverage.

Property assets are held to provide real returns to with-profits life and pension contracts. The loss absorbing capacity of with-profits contracts mitigates a proportion of the property risk.

#### **Credit Spread Risk**

Spread risk arises on corporate bond assets and represents the reduction in market value of a bond asset due the widening of credit spreads following a downgraded assessment of asset quality.

The Society has a potentially large exposure to this risk as the risk free yield curve is used to derive the valuation interest rate used to discount liabilities. Thus the value of non-profit liabilities does not change under this stress and hence there is no compensation for the loss in value of assets under the stress. The loss absorbing capacity of with-profits contracts mitigates a proportion of the credit spread risk on corporate bonds held to back those contracts; as at 31 December 2023 no corporate bonds were held to back non-profit contracts, therefore there was no credit spread risk in respect of those liabilities.

In relation to the pension scheme, under FRS 102 liabilities are discounted using spread from a corporate bond index, and part of the assets are invested in corporate bonds. Therefore to the extent that the liability discount rate and asset yields do not move in line with each other, a credit spread risk arises.

#### **Currency Risk**

This arises when movements in foreign exchange rates have an adverse impact on the value of the Society's assets or liabilities. All liabilities are denominated in Sterling, as are all directly held assets. Any exposure to currency risk form indirectly held assets is minimal.

# Assessment and risk mitigation techniques

The Society has processes in place to limit and monitor market risks:

- The risk register contains key market risks and is reviewed quarterly with a summary reported to the Risk and Compliance Committee on a quarterly basis.
- Regular cash flow analysis takes place and is monitored internally by the Capital Management and Investment working Group.
- Projected liability cashflows are provided to the Society's asset managers in order to ensure asset liability matching remains appropriate.
- A regular review of assets held against Own Funds takes place at Investment Committee Meetings.
- Investment mandates specify maximum exposure limits to lower quality bond assets.
- A process is in place whereby management are informed before any transactions take place that would adversely impact the average credit rating of the bond portfolios.
- Daily monitoring of investment indices takes place to identify the movement in key investment metrics with triggers set to prompt consideration on any actions that should be taken in response.
- New product terms are tested for their sensitivity to market risk as part of the profit testing work.

# **Prudent Person Principle**

The PRA Rulebook requires that the "Prudent Person Principle" is applied to the Society's investments. The Society adheres to the principle by investing in a range of equity, property and fixed interest assets of an appropriate quality and level of diversification. There are also holdings in cash to mitigate the impact of adverse market movements and interest rate swaps to minimise any mismatch of durations in market movements between assets and liabilities.

The weightings of the different asset classes and the nature of the underlying assets are regularly monitored and are reviewed quarterly by the Investment Committee to consider their appropriateness to the matching requirements of the technical provisions and the best interests of policyholders.

#### Risk sensitivity for market risk

The Society assesses market risk by considering a number of stand-alone stress tests and scenarios affecting material market assumptions within its ORSA. These consider the impact of an immediate shock to the starting balance sheet in addition to the impact on its forward-looking assessment of the future balance sheet position.

#### C.3 Credit Risk

#### **Material Credit risks**

The risk of credit spreads widening has been covered in Section C.2.

# **Counterparty Default Risk**

This risk arises when a counterparty is unable to fulfil its obligations to the Society, thereby leading to a loss of the Society's financial assets. The key exposures are money market deposits, reinsurance assets and derivative contracts.

#### Assessment and risk mitigation techniques

The Society has processes in place to limit and monitor counterparty default risk:

- The risk register contains key default risks and is reviewed quarterly with a summary reported to the Risk and Compliance Committee on a quarterly basis.
- The Society's risk appetite statement sets thresholds for counterparty exposure in terms of monetary limits per counterparty and credit quality standing of counterparties. These are monitored regularly through the Risk and Compliance Committee.
- Selection of new reinsurance terms has regard to minimum credit rating criteria.

# Risk sensitivity for counterparty default risk

This is not currently considered a significant risk for the Society, however, fulfilment of the strategic plan sales volumes will result in increased exposure to reinsurance over the planning period. The reinsurers have strong credit ratings which minimises this risk.

# C.4 Liquidity Risk

This is the risk that the Society is not able to meet its financial obligations to policyholders and other creditors when they become due and payable, at a reasonable cost and in a timely manner. Liquidity risk is not quantified in the Solvency Capital Requirements.

# Assessment and risk mitigation techniques

Short-term liquidity or daily cash management covers the day-to-day cash requirements under normal business operations. Long-term liquidity is managed through careful matching of liabilities and their expected cash outflows against assets of similar duration. With the exception of property assets, most of the Society's assets are readily realisable, providing a high degree of mitigation of liquidity risk.

The Capital Management, Investments and Liquidity Working Group meets monthly to review the latest cashflow forecasts, and to decide whether management action needs to be taken to address any risk of liquidity shortfall over the following 3-6 months.

#### Risk sensitivity for liquidity risks

The Society has set a risk appetite measure to maintain minimum cash deposits that would be sufficient to cover a minimum of three months projected claims and expense outgoings in order to allow sufficient time to realise the most appropriate investments in the event of a stress scenario. It is likely that there will be further reductions in the value of the Society's asset portfolio over 2024 reflecting the maturing profile of the Society's business, combined with sales of protection contracts that require initial financing. The Society's Investment & Liquidity Policy ensures it will have sufficient readily realisable assets to meet these requirements over the coming year in accordance with its risk appetite measure.

# **C.5** Operational Risk

Operational risk is the risk of direct or indirect loss (actual or potential) resulting from inadequate or failed internal processes, people and systems or from external events. This includes risks relating to compliance, business processes, information technology, outsourcing and financial reporting.

# Assessment and risk mitigation techniques

The Society's Operational Risk policy defines the key operational risks faced and the processes in place to identify, assess, manage, monitor and report risks and events.

The following processes are in place to manage operational risk:

- Well-established Risk function regularly performs operational risk monitoring, in order to assist in detecting deficiencies in the policies, procedures and processes of the Society and propose corrective actions.
- The Risk function is subject to independent periodic review by internal audit.
- All departmental functions of the Society are required to conduct risk assessments, which
  include specific operational risks inherent in their activities, including their identification and
  assessment with regard to the likelihood and impact on the Society, and report the identified
  events to through the Society's automated risk management system.
- Defined key risk indicators, to act as early warnings of increased risk of potential losses.
   Effective tracking of these indicators by the Risk function allows the Society to identify changing risks upon their occurrence and respond to them promptly.
- Insurance is in place to protect against losses, which may occur as a result of events such as third-party claims resulting from errors and omissions, employee or third-party fraud, and natural disaster.
- Disaster recovery and business continuity plans are in place for all key functions/departments and take into account different types of plausible scenarios to which the Society's operations may be subject. Such plans are periodically reviewed and tested.
- All outsourced activities are subject to due diligence and regular review and monitoring.

#### Risk sensitivity for operational risks

This is not currently a significant financial risk for the Society however, the planned increase in new business could increase the exposure to operational risk and this will be closely monitored by the Society.

#### **Conduct Risk**

Conduct risk has the potential to arise if the Society's behaviours result in poor customer outcomes; it is inherent in any operation that provides products or services to customers. Delivering good customer outcomes is a key driver in building a valuable, sustainable business and is a key measure as part of the Society's risk appetite. The implementation work being undertaken by the Consumer Duty project is helping to mitigate conduct risk for the Society.

The Society's products are distributed through both regulated intermediaries and direct sales. All employed Sales Executives are subject to strict training and competence requirements, monitoring by direct management and compliance oversight.

Regular conduct risk training is completed for all staff members, with more in-depth training for individuals undertaking sales and customer service roles. Additionally, a number of processes are in place to manage and monitor conduct risk exposures across the end-to-end customer journey. Conduct risk processes are subject to review and challenge as part of the internal monitoring plan, and oversight through the Compliance function.

# C.6 Other Material risks

There are no other material risks to disclose.

# **D** Valuation for Solvency Purposes

#### D.1 Assets

#### Summary of asset valuation

The table below summarises the Society's assets valued for solvency purposes and per the financial statements (FRS102) as at 31 December 2023:

Assets (£'000)	FRS 102	Solvency
Intangible assets	229	-
Pension surplus	1,673	1,673
Property, plant & equipment	2,604	2,604
Investments	45,053	43,051
Assets held to cover linked liabilities	1,563	1,563
Loans and mortgages	908	908
Reinsurance asset <sup>1</sup>	-5,266	-5,266
Insurance and intermediaries receivables	237	237
Trade receivables (not insurance)	378	378
Cash and cash equivalents	3,723	3,723
Other assets	2,656	2,656
Total assets	53,758	51,527

<sup>&</sup>lt;sup>1</sup>The reinsurance asset represents the Technical Provisions associated with the reinsured policies that have been ceded to a reinsurer, as outlined in section D.2. At the year end, it is in a payable position and therefore negative, but must be accounted for in this manner for solvency purposes.

#### Differences between valuation for solvency purposes and valuation in financial statements

Assets on the Society's solvency balance sheet are typically valued on the same basis as applied in the financial statements under FRS 102 aside from the following exceptions:

- Under the PRA Rulebook, the Society's intangible assets are valued at nil as there are no quoted prices in an active market for similar assets.
- Under the PRA Rulebook, the Society's investments in subsidiaries are valued on a look through basis. Therefore, intangible assets contained within the subsidiaries are also valued at nil as there are no quoted prices in an active market for similar assets.

The Society has a deferred tax asset comprising of capital losses, expenses deductible from future years and trade losses. This asset may be realised through reduced future tax payable, when net gains chargeable to corporation tax generate sufficient taxable income to offset the expenses or losses. However, the Society is currently in a position of expenses allocated to taxable BLAGAB exceeding investment income allocated to taxable BLAGAB and it is uncertain when this asset could be realised.

Therefore, no deferred tax asset has been recognised on the Balance Sheet for solvency or FRS102 purposes.

The table below presents the Society's assets as at 31 December 2023 under FRS 102 and solvency bases. All values are shown in £'000s with the categories aligned to FRS 102 and solvency reporting.

FRS 102 description	FRS 102 value	Solvency description	Solvency value
Intangible assets	229	Intangible assets	-
Net pension asset	1,673	Pension benefit surplus	1,673
Investment Property	4,325	Property (other than for own use)	4,325
Investment in subsidiaries	541	Holdings in related undertakings	55
Fixed interest securities	36,626	Government bonds	25,269
Listed shares	1,950	Corporate bonds	9,880
Investment cash	1,563	Collateralised securities	-39
Mortgages	48	Collective investments	1,950
		undertakings	
		Deposits other than cash equivalents	1,563
		Loans and mortgages to individuals	48
Subtotal	45,053	Subtotal	43,051
Assets held to cover linked liabilities	1,563	Assets held for index-linked and unit-linked contracts	1,563
	F 266		F 266
Reinsurance asset/(payable)	-5,266	Reinsurance recoverable from: Life and health similar to life excluding	-5,266
		index-linked and unit-linked	
Debtors	909	Loans on policies	37
		Other loans and mortgages	823
		Insurance and intermediaries	48
		receivables	
		Subtotal	909
Other assets	6,327	Property, plant & equipment held	2,604
		for own use	
		Cash and cash equivalents	3,723
		Subtotal	6,327
Prepayments and accrued income	3,270	Receivables (trade, not insurance)	378
		Insurance and intermediaries receivables	237
		Any other assets, not elsewhere shown	2,656
		Subtotal	3,271
Total	53,759	Total	51,527

Valuation of most financial assets is on a fair value basis with no changes made to the recognition and valuation bases during the reporting period. The paragraphs below further describe the valuation methodologies applied to each asset category.

#### Fair value measurement

Where applicable, the Society measures the fair value of a financial instrument using the quoted price in an active market for that instrument. If unavailable, the Society uses the valuation hierarchy summarised below to determine the fair value when accounting for assets and liabilities. This is in line with the valuation methodology set out in the PRA Rulebook.

#### Fair value based on quoted prices in an active market

The default method is to value assets and liabilities using unadjusted quoted market prices in active markets for the same assets or liabilities.

A market is defined as active if:

- Quoted prices are readily available e.g. from an exchange, broker or dealer;
- These prices represent actual regularly occurring transactions on an arm's length basis.

#### Fair value based on observable market data

Where the use of quoted market prices in an active market is not possible, assets and liabilities are valued using techniques based significantly on observed market data. These observable inputs are obtained from a broker or third party pricing services and include:

- Quoted prices in active markets for similar (not identical) assets or liabilities.
- Quoted prices for identical or similar assets in inactive markets.
- Input variables, which are based on or supported by observable market data.

#### Fair value not based on observable market data

Alternative valuation techniques are used to the extent that observable market data is not available. These reflect management's expectations about the assumptions that market participants would use in pricing an asset or liability (including assumptions about risk).

# Property (other than for own use)

The Society recognises property at market value based on observable market data. This applies the latest valuation (as at 31 December 2023) performed by the Society appointed Chartered Surveyors in accordance with the requirements of the Royal Institution of Chartered Surveyors' Valuation - Professional Standards. In preparing these valuations, data and available information concerning rental yields, lease terms, voids and floor areas and enquiries within the local market were used as contributing factors to calculate each individual property's valuation.

# Holdings in related undertakings

Valuations of holdings in related undertakings such as investments in subsidiaries is at fair value. Judgement is applied to assess the fair values of the subsidiary companies which are not considered to be materially different from the net asset value of the respective subsidiaries.

For solvency purposes (as outlined on Page 35), the holdings must be valued on a look through basis, considering the underlying assets of the subsidiary companies. Included within the FRS 102 valuation of these undertakings are intangible assets linked to an acquired book of business and the Policy Administration System. On a solvency basis, these assets are valued at nil as there are no quoted prices for a similar asset in an active market, thus reducing the value of holdings in related undertakings from £514,000 under FRS102 to £55,000 for solvency purposes.

#### Bonds - including Government bonds, Corporate bonds and Collateralised securities

Government bonds comprise UK gilts and Treasury bonds. The valuation of gilts is based on quoted market prices in an active market, whilst the valuation of Treasury bonds and other fixed-interest securities including corporate bonds are based on observed market data of same or similar assets.

#### **Collective investment undertakings**

Valuation of collective investments undertakings is based on quoted market prices in an active market.

#### Deposits other than cash equivalents

Deposits other than cash equivalents consist of cash held on fixed term-deposits with a maturity date greater than 3 months and cash held with investment managers for investment purposes. This is valued by taking the cash balances held, including the deposit interest accrued up to the balance sheet date.

#### Loans and mortgages to individuals

Loans and mortgages to individuals are valued based upon the discounted cash flow method, utilising appropriate interest rates.

#### Loans on policies

These are valued based upon the actual amounts outstanding.

#### Other loans and mortgages

This asset category comprises the claims float which is held in a separate bank account and used to pay third party administered healthcare claims together with loans to subsidiaries. The value reflects the actual amount as at the balance sheet date and does not include any further mortgages outstanding.

#### Assets held for index-linked and unit-linked contracts

These assets are part of an investment fund which is not traded on a listed market. Therefore the valuation is based on observed market data of same or similar assets.

#### Reinsurance recoverable from: Life excluding health and unit-linked

The reinsurance asset represents the Technical Provisions associated with the reinsured policies that have been ceded to a reinsurer. This asset has been valued for solvency purposes in line with the Technical Provisions as described in section D.2. As at the year end the Reinsurance is in a payable position so is negative, but must be accounted for in this manner for solvency purposes.

### Insurance and intermediaries receivables

The valuation of these assets represents the amounts owed at the valuation date.

### Property, plant & equipment held for own use

Property, plant & equipment are held at fair value using observable market data where available or alternative valuation method. This includes the owner occupied floors of the Society's head office, shown at fair value. Other assets (such as IT and office equipment) used by the Society are valued at cost less depreciation. The Society deems this to be a reasonable estimate for the replacement cost of these assets.

### Cash and cash equivalents

This comprises liquid cash holdings valued at their actual year end balances.

### Receivables (trade, not insurance)

There is no difference between the solvency valuation and the FRS 102 valuation.

### Any other assets, not elsewhere shown

The amount includes a prepayment of £2.4m to National Friendly Software Solutions Limited in respect of a 10 year license agreement of the policy administration system. The value represents the actual amount of the license charges for the remainder of the license agreement.

The Society leases office equipment under cancellable operating lease agreements.

### **D.2** Technical Provisions

#### **Analysis of Technical Provisions**

The tables below show the Technical Provisions split by line of business and between the Best Estimate Liability and Risk Margin. The only (theoretical) difference in the valuation of Technical Provisions for solvency purposes and the Long Term Business Provision shown in the financial statements is that the TMIR is included in the former but not the latter – however as previously noted, the TMIR as at 31 December 2023 was zero (hence the figures in the two tables below are the same).

Technical Provisions at 31 December 2023:

Analysis of Technical Provisions (£'000)	Gross Best Estimate Liabilities	Risk Margin	Value of Technical Provisions for solvency purposes
With-Profits Contracts	26,352	72	26,424
Other Life	-16,668	2,455	-14,213
Health Similar to Life	12,282	423	12,705
Unit Linked	1,381	17	1,398
Total	23,348	2,966	26,314

The Best Estimate Liabilities shown above is a net figure, comprising some product lines whose aggregate BEL is positive, and others whose aggregate BEL is negative. These subsets are shown below, reconciling to the total gross BEL set out in the above table:

Netting of positive and negative BEL (£'000)	Gross Best Estimate Liabilities
Product classes with net positive liabilities	73,090
Product classes with net negative liabilities	-49,742
Total	23,348

There are a small number of contracts that have both health and life assurance benefits. The majority of risk arises from the health benefits and they have therefore, been classified as Health Similar to Life Techniques in the above table.

Reinsurance recoverables are not included in the gross Technical Provisions above as the net recoverable is captured within the asset valuation. At 31 December 2023, the value of reinsurance recoverables was (£5,266k). This item is a net liability as the value of future reinsurance premiums payable exceeds the value of expected reinsurance claims recoverable.

The key characteristics of the methodology and assumptions used for the Technical Provisions are as follows:

- The BEL is calculated using best estimate assumptions which therefore by definition do not include margins for adverse deviation in each assumption;
- The best estimate cash flows are valued on a market consistent basis using UK-specific risk free discount rates prescribed by the PRA;
- Where the BEL for a group of similar contracts is negative, this has been allowed in the Technical Provisions;
- A Risk Margin is required under the solvency regulations. This represents the cost of capital that another insurance undertaking would require to take on the Society's insurance liabilities using the prescribed 4% cost of capital rate (ie allowing for the changes to the calculation which were implemented as at 31 December 2023).

The PRA Rulebook permits a number of simplifications in the calculation of the Technical Provisions. The key simplification applied by the Society relates to the calculation of the Risk Margin whereby the projected future SCR used to determine the cost of capital is approximated using the profile of the BEL or policy run off, as appropriate (e.g. to allow for products with negative BEL).

There are a number of approximations used in the calculation of the BEL which reflect proportionality and align with generally accepted actuarial practice. These include:


- Allowance for tax as a percentage of investment return and expenses which reflect the tax regime of a friendly society;
- Use of annual cash flows in stochastic calculations;
- Age approximations on joint life policies.

#### **Main Assumptions**

#### **Valuation Discount Rates**

The valuation interest rate used to discount the BEL and Risk Margin is the relevant GBP risk free term structure of interest rates as at 31 December 2023 and provided by the PRA. The risk free yield curve has not been adjusted in respect of a matching adjustment or a volatility adjustment.

Risk free rates reduced slightly during 2023, at short and medium durations, as shown below.



The Society has been approved by the PRA to use TMIR.

This allows firms a transitional period to move from the interest rate structure in force under the previous regime ("Solvency I") to that required by the current regime over a period of 16 years, in respect of insurance contracts in force prior to 1 January 2016. The benefit therefore reduces as those liabilities run off, and as the 16 year amortisation works its way through. It is also sensitive to the assets actually held by the Society, and for these reasons the assessed value as at 31 December 2023 was immaterial, hence a value of zero has been used for the TMIR.

### **Expenses**

Best estimate per-policy expenses have been calculated taking into account the anticipated new business the Society expects to write.

The methodology is based on setting per policy expenses such that they equal the anticipated maintenance expenses in 4 years' time divided by the expected number of policies in force at that time. The expected number of policies is based on the run-off of the Society's current in-force book plus projected new business.

The expense inflation assumption is set by reference to:

- The assumed future rate of inflation of salary related expenses, which is based on Societyspecific factors in the short term, and an increment above assumed general inflation in the long term.
- The assumed future rate of inflation of non-salary related expenses, which is based on a
  market implied RPI inflation rate, adjusted for differences between RPI and CPI and for an
  inflation risk premium. Inflation projections from the Bank of England are also used as a
  reference point.
- The two components above are then blended to reflect the salary and non-salary related proportions of the Society's renewal expense base.

The assumed investment expenses are based upon the contractual investment expenses paid by the Society to its asset managers.

#### <u>Lapses</u>

Lapse assumptions are set with reference to actual experience for homogeneous groups of contracts. For certain contracts where a significant change in terms applies at a specific point in time, one off lapse assumptions have been determined based on prior experience.

Lapse rates were updated in the calculation of Technical Provisions at 31 December 2023 based upon actual experience per product group and expert judgement. The change in assumptions varied according to product groups.

### **Morbidity Assumptions**

Best estimate morbidity assumptions are determined based upon analysis of the Society's own experience and are established separately for each homogeneous group where sufficiently credible data exists.

For some contracts, an assumption for inflation of future medical expenses is required. This is set having regard to own experience, restrictions in benefits payable and general inflation assumptions.

Morbidity assumptions were updated in the calculation of Technical Provisions at 31 December 2023 based on actual experience and expert judgement. The change in assumptions varied according to product groups.

### **Mortality Assumptions**

Mortality assumptions are set with reference to analysis of the Society's own experience having regard to standard actuarial tables of mortality rates. Assumptions are determined separately for each homogeneous group where sufficiently credible data exists.

For contracts with higher levels of mortality risk, the rates used vary between males and females and between smokers and non-smokers. Annuitant mortality rates are adjusted for projected mortality improvements, using relevant projections from the Continuous Mortality Investigation ("CMI").

Mortality assumptions were updated in the calculation of Technical Provisions at 31 December 2023 based on actual experience and expert judgement. The change in assumptions varied according to product groups.

#### Material assumption changes

The Society has reviewed its experience against that expected and has made a number of changes to its assumptions of future experience in the light of that analysis. The most significant changes at 31 December 2023 are:

- Mortality assumptions have been strengthened on average, increasing the BEL by £1.2m.
- Morbidity assumptions have been strengthened on average, increasing the BEL by £1.7m.

### Uncertainty associated with the value of the Technical Provisions

Uncertainty arises from actual experience being different to the assumptions used in the calculation of the Technical Provisions.

Assumptions with the most uncertainty are as follows:

- Longevity assumptions. The Society has a number of annuity contracts which are sensitive to
  longevity assumptions, including with profit retirement annuity contracts with valuable
  guarantees. The Society's staff defined benefit pension scheme is also sensitive to longevity
  assumptions. In some categories the volume of business is insufficient to inform a credible
  experience analysis and so there is increased uncertainty around these assumptions.
- Mortality and lapse assumptions on the GLA/GLAP contracts. These are still relatively new
  products and therefore the Society has limited relevant data on which to base long term
  assumptions, and hence there is greater uncertainty around these assumptions. Experience
  is being closely monitored.
- Expense assumptions are calculated with reference to future new business volume projections. The actual volumes of new business may be higher or lower than those forecast.
- Whilst the Society has a reasonable amount of historic data on which to base assumptions, morbidity assumptions continue to be uncertain as the book ages and as events such as premium reviews and the after effects of the COVID pandemic could trigger changes in experience.

### Methodology

Technical Provisions are defined as the sum of the BEL and the Risk Margin. The BEL and Risk Margin are calculated separately. The Society does not apply a matching or volatility adjustment but does apply an adjustment for TMIR on the BEL, as previously described. In line with Guideline 2 of the EIOPA "Guidelines on the implementation of the long-term guarantee measures" the TMIR does not apply to the Risk Margin.

The impact of the TMIR on the Society's Own Funds, SCR and Minimum Capital Requirement ("MCR") is discussed in section E.1 Own Funds and section E.2 Solvency and Capital Requirement and Minimum Capital Requirement.

The Society does not apply a transitional measures on technical provisions.

### **Best Estimate of Liabilities**

The Society has a data warehouse from which individual policy data is extracted and validated for completeness and accuracy. This data is used to calculate the Technical Provisions and SCR and has passed an appropriate level of controls.

The BEL is calculated on a policy by policy basis for all contracts accepted on risk at the valuation date using a cash flow approach and generally accepted actuarial practices. The calculations generate probability weighted cashflows for each monthly time period within a policy's contract boundary. The cash flows are discounted using the PRA risk free yield curve and therefore allow appropriately for the time value of money.

The BEL is calculated gross of reinsurance recoverables which are calculated separately. If the present value of future cash flows on a contract gives rise to a negative BEL, this has been allowed.

For with-profit contracts, total reserves are calculated as the higher of the asset share or basic reserve at a Homogenous Risk Group ("HRG") level plus other future policy related liabilities. The basic reserve is calculated as the discounted value of probability-weighted cashflows. This covers the expected future guaranteed benefits payable at exit (death, maturity or surrender) on bonuses declared up to the valuation date, plus the value of expense loadings assumed within the premiums, less the value of future gross premiums. Surrender penalties are applied where appropriate in line with the Society's current practice on early surrenders.

Asset shares are accumulated using forward rates derived from the required risk free rates at the valuation date in line with a risk neutral approach.

The other future policy-related liabilities consist of an additional expense reserve, cost of guarantees and planned deductions for guarantees on other HRGs. The additional expense reserve has been calculated by valuing assumed per policy costs over the future lifetime of each contract less the amounts already allowed for within the future premium values (as described above). The investment expense reserve is set to zero because investment returns credited to asset shares are net of investment expenses.

Stochastic methods are used to determine the value of financial guarantees/options on with-profits pension and bond contracts.

### Risk Margin

The total Risk Margin is calculated as the sum of the present values of the cost of capital rate applied to the SCR of a reference undertaking, willing to take on the Society's insurance portfolio, in each future year until the obligations are extinguished and there is no remaining SCR. The future SCRs are modelled using a permitted simplification whereby the SCR is assumed to be proportional to the projected best estimate of liabilities for each group of similar contracts. In line with the changes introduced from 31 December 2023, a tapering factor is applies to the projected SCRs.

The Risk Margin has been calculated by applying the Society's non-hedgeable capital requirements arising under the Standard Formula SCR directly to the reference undertaking without adjustment. The defined benefit pension scheme is not included in the Risk Margin calculation. Non-hedgeable risk arises under the Life and Health Underwriting Risk modules, the Operational Risk module and a subset of the Counterparty Default Risk module. Market risk and residual counterparty default risk are assumed to be fully hedged.

#### **D.3** Other Liabilities

### Summary of the other liabilities

The table below shows the valuation of the Society's other liabilities on FRS 102 and solvency bases. There is no difference between the valuation of the liabilities on the Society's solvency balance sheet and the basis applied in the financial statements under FRS 102. Values shown are in £'000s

FRS 102 description	FRS 102 value	Solvency description	Solvency value
Creditors	4,095	Insurance & intermediaries payables	-713
		Payables (trade, not insurance)	154
		Any other liabilities, not elsewhere	4,654
		shown	
		Subtotal	4,095

### **Derivatives**

No derivatives were held as at the year-end.

### Pension benefit obligations

The Society previously operated a defined benefit pension scheme, the National Deposit Friendly Society Staff Superannuation Fund ("the SSF") for its employees. The SSF was closed to future accrual of benefits with effect from 31 May 2009. All remaining active members were treated as having left Pensionable Service with effect from that date. These members receive increases in deferment equal to the higher of the increase in their pensionable salary and statutory deferred revaluation while they remain at the Society. The operation of the SSF is overseen by the trustees with the scheme assets held separately to those of the Society.

The latest formal actuarial valuation of the SSF for funding purposes was carried out as at 31 December 2022. Separately, for the purposes of the accounting and solvency balance sheets a valuation is undertaken at each year end by a qualified independent actuary in line with IAS 19. As at 31 December 2023 these calculations indicated that the SSF has a net surplus of £1,673k. FRS 102 has been brought in line with the International Financial Reporting Standards, and in the opinion of the actuaries who calculated the FRS 102 position, the surplus or deficit under IAS 19 (consistent with the solvency basis) would be materially the same. As such, there is no difference between the FRS 102 and solvency valuations. Activity has been undertaken to satisfy the Directors that the value of the surplus would be realisable in future and therefore can appropriately be held on the balance sheet.

Further details regarding the composition of assets and methodology used to value the pension scheme liabilities can be found within the Society's Financial Statements.

The valuation of all other categories of liabilities follows the solvency basis fair value hierarchy as described in section D.1. There is no difference between the solvency valuation and the FRS 102 valuation of these liabilities.

# **Contingent liabilities**

The Society has no contingent liabilities.

There were no changes made to the recognition and valuation bases applied to other liabilities during the reporting period.

# D.4 Alternative methods for valuation

The Society does not use any alternative methods for the valuation of liabilities.

# **E** Capital Management

### E.1 Own Funds

### Objective, policies and processes for managing Own Funds

The Society is a mutual organisation as defined by the Friendly Societies Act 1992. It does not have shareholders and the Society's assets and Own Funds are ultimately owned by the Society's members or policyholders.

Own Funds represent the excess of assets over Technical Provisions, which are invested principally in secure assets, to ensure that their value is maintained in a stress scenario and that any losses in the value of assets backing liabilities can be covered. The allocation of these assets is set out in the Society's Investment & Liquidity Policy, with the level of risk associated with these assets being explicitly linked to the degree to which the Society's Solvency Risk Appetite is being met. Overall, the assets aim to generate positive returns for policyholders subject to an acceptable level of risk, compliance with regulatory requirements and the required level of liquidity.

The Society aims to manage its funds such that there is an appropriate margin of Own Funds over the SCR at all times. This is monitored formally through the quarterly Risk and Compliance Committee and on an ongoing basis by the Actuarial Function.

The Society considers that all Own Funds meet the definition of 'surplus funds' as per Article 91 of the original Solvency II Directive:

"Surplus funds shall be deemed to be accumulated profits which have not been made available for distribution to policy holders and beneficiaries."

Furthermore, all Own Funds are categorised as Tier 1 capital.

Business planning is performed annually, spanning a five-year projection period and is reported in the Society's Own Risk and Solvency Assessment with ongoing monitoring of business performance versus the ORSA target.

### Own Funds classified by tiers

Own Funds are classed as Tier 1 capital and are presented in the table below:

Solvency Balance Sheet (£'000)	2023	2022
Assets	53,084	65,020
Best Estimate Liabilities	23,348	40,888
Other Liabilities	4,095	1,503
Risk Margin	2,966	5,014
Total Liabilities	30,409	47,404
Eligible Own Funds	22,714	17,615

The main reasons for the change in Own Funds from £17.6m at 31 December 2022 to £22.7m at 31 December 2023 are:

-£2.0m: Changes in demographic assumptions
 +£1.0m: Changes in economic valuation assumptions
 +£2.5m: Movements in inforce business
 +£3.6m: Impact of writing new business (excluding expense overruns)
 -£1.6m: Strategic expenses/expense overruns
 -£1.3m Change in pension fund position

• -£0.3m: Model changes

### **Reconciliation from Fund for Future Appropriations to Own Funds**

The Society's Own Funds equate to the Fund for Future Appropriations referenced within the Society's Financial Statements subject to adjustments for a small number of valuation differences as described in sections D.1 and D.2.

Financial Statements to Solvency reconciliation	£'000s
Fund for future appropriations	23,239
Less: Intangible asset	(229)
Less: Investment in subsidiary valuation difference	(296)
Plus: Impact of TMIR on Technical Provisions	-
Own Funds	22,714

### E.2 Solvency and Capital Requirement and Minimum Capital Requirement

The amount of SCR and MCR are shown in the table below.

(£'000)	2023	2022
SCR	15,364	12,395
MCR	3,841	3,445

### **SCR Split by Risk Module**

The Society uses the Standard Formula as set out in the PRA Rulebook to calculate the SCR and does not use any undertaking specific parameters. The risk module capital requirements are calculated without using simplifications.

The table below sets out the undiversified net SCR for each of the risk modules.

Undiversified net SCR (£'000)	2023	2022
Market Risk	3,627	3,736
Counterparty Risk	637	374
Underwriting Risk (Life)	17,227	13,247
Underwriting Risk (Health SLT)	2,853	3,244
Operational Risk	1,251	1,044

The overall SCR has increased in absolute terms driven by a continued increase in life underwriting risk, in turn largely due to the strong growth of the GLAP product, which generates material lapse and mortality risk. In particular they generate significant negative reserves which are exposed to the mass lapse scenario which is the biting lapse stress, although reinsurance executed during 2022 has reduced the exposure to this mass lapse risk.

Note that the final SCR is subject to supervisory confirmation.

#### **MCR**

The components of the MCR calculation are shown below. The absolute floor of the MCR is prescribed by the PRA Handbook rules as €4m for an insurer with long-term liabilities. This equates to £3.495m in pounds sterling using the prescribed exchange rate for year end 2023.

At 31 December 2023 the MCR absolute floor was less than 25% of the SCR, therefore the MCR is equal to the MCR floor, ie 25% of SCR.

Overall MCR calculation (£'000)	2023	2022
Linear MCR	818	1,247
SCR	15,495	12,395
MCR cap (45% of SCR)	6,914	5,987
MCR floor (25% of SCR)	3,841	3,410
Combined MCR	3,841	3,410
Absolute floor of the MCR	3,495	3,445
MCR	3,841	3,445

### E.3 Use of Duration-based Equity Risk Sub-module

The Society does not use the duration-based equity risk sub-module.

### E.4 Differences between Standard Formula and internal model

The Society uses the Standard Formula to assess its SCR.

### E.5 Compliance with MCR and SCR

The Society performed a full valuation as at 31 December 2023, valuations close to full valuations but with some approximations at other quarter ends, and approximate solvency estimates at other month ends.

The Society maintained sufficient funds throughout 2023 to cover its MCR and SCR.

# **APPENDIX**

# **Appendix 1** Quantitative Reporting Templates

The following Quantitative Reporting Templates ("QRTs") are required for the SFCR. All figures are presented in thousands of pounds with the exception of ratios that are in decimals. Please note that totals may differ from the component parts due to rounding.

QRT Ref	QRT Template name
S.02.01.02	Balance Sheet
S.05.01.02	Premiums, claims and expenses
S.05.02.01	Premiums, claims and expenses by country
S.12.01.02	Life and Health SLT Technical Provisions
S.23.01.01	Own Funds
S.25.01.21	Solvency Capital Requirement – for undertakings on Standard Formula
S.28.01.01	Minimum Capital Requirement – Only Life or only non-life insurance or reinsurance activity

#### General information

Undertaking name
Undertaking identification code
Type of code of undertaking
Type of undertaking
Country of authorisation
Language of reporting
Reporting reference date
Currency used for reporting
Accounting standards
Method of Calculation of the SCR
Matching adjustment
Volatility adjustment

National Deposit Friendly Society Limited
21380062E42V3LV4Y497
LEI
Life undertakings
GB
en
31 December 2023
GBP
Local GAAP
Standard formula
No use of matching adjustment
No use of volatility adjustment
No use of transitional measure on the risk-free interest rate
No use of transitional measure on technical provisions

#### List of reported templates

5.02.01.02 - Balance sheet

S.05.01.02 - Premiums, claims and expenses by line of business

5.05.02.01 - Premiums, claims and expenses by country

S.12.01.02 - Life and Health SLT Technical Provisions

Transitional measure on the risk-free interest rate Transitional measure on technical provisions

S.23.01.01 - Own Funds

5.25.01.21 - Solvency Capital Requirement - for undertakings on Standard Formula

5.28.01.01 - Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

3.723

2,656

53,081

R0410 Cash and cash equivalents

R0500 Total assets

R0420 Any other assets, not elsewhere shown

#### 5.02.01.02 **Balance sheet** Solvency II value C0010 R0030 Intangible assets R0040 Deferred tax assets R0050 Pension benefit surplus 1,673 R0060 Property, plant & equipment held for own use R0070 Investments (other than assets held for index-linked and unit-linked contracts) 44,566 Property (other than for own use) 4,325 R0080 R0090 Holdings in related undertakings, including participations 55 R0100 Equities R0110 Equities - listed R0120 Equities - unlisted R0130 Bonds Government Bonds 26,880 R0140 Corporate Bonds 9,842 R0150 Structured notes R0160 Collateralised securities R0170 R0180 Collective Investments Undertakings 1,515 R0190 Derivatives R0200 Deposits other than cash equivalents 1,950 R0210 Other investments R0220 Assets held for index-linked and unit-linked contracts 1,563 R0230 Loans and mortgages 908 908 R0240 Loans on policies R0250 Loans and mortgages to individuals R0260 Other loans and mortgages R0270 Reinsurance recoverables from: -5.227 R0280 Non-life and health similar to non-life R0290 Non-life excluding health R0300 Health similar to non-life R0310 Life and health similar to life, excluding index-linked and unit-linked -5.227 R0320 -5,271 Health similar to life R0330 Life excluding health and index-linked and unit-linked 44 R0340 Life index-linked and unit-linked 0 R0350 Deposits to cedants 0 R0360 Insurance and intermediaries receivables 237 R0370 Reinsurance receivables R0380 Receivables (trade, not insurance) 378 R0390 Own shares (held directly) R0400 Amounts due in respect of own fund items or initial fund called up but not yet paid in

# S.02,01.02 Balance sheet

		Solvency II value
	Liabilities	C0010
R0510	Technical provisions - non-life	0
R0520	Technical provisions - non-life (excluding health)	0
R0530	TP calculated as a whole	
R0540	Best Estimate	
R0550	Risk margin	
R0560	Technical provisions - health (similar to non-life)	0
R0570	TP calculated as a whole	
R0580	Best Estimate	
R0590	Risk margin	
R0600	Technical provisions - life (excluding index-linked and unit-linked)	24,887
R0610	Technical provisions - health (similar to life)	12,401
R0620	TP calculated as a whole	0
R0630	Best Estimate	11,985
R0640	Risk margin	416
R0650	Technical provisions - life (excluding health and index-linked and unit-linked)	12,486
R0660	TP calculated as a whole	0
R0670	Best Estimate	9,981
R0680	Risk margin	2,505
R0690	Technical provisions - index-linked and unit-linked	1,399
R0700	TP calculated as a whole	0
R0710	Best Estimate	1,382
R0720	Risk margin	17
R0740	Contingent liabilities	
R0750	Provisions other than technical provisions	
R0760	Pension benefit obligations	
R0770	Deposits from reinsurers	
R0780	Deferred tax liabilities	
R0790	Derivatives	0
R0800	Debts owed to credit institutions	
R0810	Financial liabilities other than debts owed to credit institutions	
R0820	Insurance & Intermediaries payables	-727
R0830	Reinsurance payables	
R0840	Payables (trade, not insurance)	154
R0850	Subordinated liabilities	0
R0860	Subordinated liabilities not in BOF	
R0870	Subordinated liabilities in BOF	0
R0880	Any other liabilities, not elsewhere shown	4,654
R0900	Total liabilities	30,367
R1000	Excess of assets over liabilities	22,714

S.05.01.02 Premiums, claims and expenses by line of business

Life

			Line of Business for: life insurance obligations					Life reinsurar		
		Health insurance	Insurance with profit participation	Index-linked and unit-linked insurance	Other life insurance	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance obligations	Health reinsurance	Life reinsurance	Total
		C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
	Premiums written									
R1410	Gross	7,870	451	22	22,410					30,75
R1420	Reinsurers' share	2,272			5,406					7,67
R1500	Net	5,597	451	22	17,004					23,07
	Premiums earned									
R1510	Gross	7,870	451	22	22,410					30,75
R1520	Reinsurers' share	2,272			5,406					7,67
R1600	Net	5,597	451	22	17,004					23,074
	Claims incurred									
R1610	Gross	8,564	4,460	83	9,860					22,96
R1620	Reinsurers' share	2,699			5,004					7,70
R1700	Net	5,865	4,460	83	4,857					15,26
	Changes in other technical provisions									
R1710	Gross									(
R1720	Reinsurers' share									(
R1800	Net	0	0	0	0					(
R1900	Expenses incurred	4,630	953	66	15,124					20,77
R2500	Other expenses									5
	Total expenses									20,82

	Life							
		C0150	C0160	C0170	C0180	C0190	C0200	C0210
		Home Country	Top 5 countries (by	amount of gross pred obligations	miums written) - life		by amount of gross n) - life obligations	Total Top 5 and
1400		nome country						home country
		C0220	C0230	C0240	C0250	C0260	C0270	C0280
	Premiums written							
1410	Gross	30,753						30,7
1420	Reinsurers' share	7,679						7,6
1500	Net	23,074						23,0
	Premiums earned							
	Gross	30,753						30,7
1520	Reinsurers' share	7,679						7,6
1600		23,074						23,0
	Claims incurred							
	Gross	22,968						22,96
	Reinsurers' share	7,703						7,70
1700		15,266						15,20
	Changes in other technical provisions							
	Gross							
	Reinsurers' share							
1800	Net	0						
1900	Expenses incurred	20,773						20,77
2500	Other expenses							
2600	Total expenses							20,7

#### S.12.01.02 Life and Health SLT Technical Provisions

			Index-linked	d and unit-linke	d insurance	Ot	her life insuran	ce	Annuities stemming from			Health ins	urance (direct	: business)	Annuities		
		Insurance with profit participation		Contracts without options and guarantees	Contracts with options or guarantees		Contracts without options and guarantees	Contracts with options or guarantees	non-life insurance contracts and	reinsurance	Total (Life other than health insurance, including Unit-Linked)		Contracts without options and guarantees	Contracts with options or guarantees	stemming from non-life insurance contracts and relating to health insurance obligations	Health reinsurance (reinsurance accepted)	Total (Health similar to life insurance)
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0150	C0160	C0170	C0180	C0190	C0200	C0210
R0010	Technical provisions calculated as a whole Total Recoverables from reinsurance/SPV and Finite Re after										0						0
	the adjustment for expected losses due to counterparty default																
R0020	associated to TP calculated as a whole										0						0
	Technical provisions calculated as a sum of BE and RM Best estimate																
R0030	Gross Best Estimate	26,391		1,382			-16,411				11,362		11,985				11,985
R0080	Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	30					5				44		-5,271				-5,271
NOODU		37					,						-3,271				-3,271
R0090	Best estimate minus recoverables from reinsurance/SPV and Finite Re	26,352		1,382	0		-16,416	0			11,318		17,257	0			17,257
R0100	Risk margin	69	17			2,436					2,522	416					416
	Amount of the transitional on Technical Provisions																
R0110	Technical Provisions calculated as a whole										0						0
	Best estimate										0						0
R0130	Risk margin										0						0
R0200	Technical provisions - total	26,461	1,399			-13,975					13,885	12,401					12,401

#### S.23.01.01 Own Funds

	Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35
R0010	Ordinary share capital (gross of own shares)
R0030	Share premium account related to ordinary share capital
R0040	Initial funds, members' contributions or the equivalent basic own-fund item for mutual and mutual-type undertakings
R0050	Subordinated mutual member accounts
R0070	Surplus funds
R0090	Preference shares
R0110	Share premium account related to preference shares
R0130	Reconciliation reserve
R0140	Subordinated liabilities
R0160	An amount equal to the value of net deferred tax assets
R0180	Other own fund items approved by the supervisory authority as basic own funds not specified above
R0220	Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds
R0230	Deductions for participations in financial and credit institutions
R0290	Total basic own funds after deductions
	Ancillary own funds
R0300	The state of the s
R0310	7,
R0320	Unpaid and uncalled preference shares callable on demand
R0340	
R0350	Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/FC
R0360	Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC
	Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC
	Other ancillary own funds  Total ancillary own funds
KU4UU	
	Available and eligible own funds
	Total available own funds to meet the SCR
	Total available own funds to meet the MCR
	Total eligible own funds to meet the SCR
KU550	Total eligible own funds to meet the MCR
R0580	SCR
R0600	
R0620	
R0640	Ratio of Eligible own funds to MCR
	Reconcilliation reserve
R0700	Excess of assets over liabilities
	Own shares (held directly and indirectly)
	Foreseeable dividends, distributions and charges
	Other basic own fund items
	Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds
R0760	Reconciliation reserve
0.0770	Expected profits
	Expected profits included in future premiums (EPIFP) - Life business
	Expected profits included in future premiums (EPIFP) - Non- life business Teach Expected profits included in future premiums (EPIFP) - Non- life business
KU/90	Total Expected profits included in future premiums (EPIFP)

Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
C0010	C0020	C0030	C0040	C0050
0	0		0	
0	0		0	
0	0		0	
0	00.486	0	0	0
22,675 0	22,675	0	0	0
0		0	0	0
39	39		•	
0		0	0	0
0				0
0	0	0	0	C
0				
0	0	0	0	
22,714	22,714	0	0	0
_				
0			_	
0				
0				
0				
0				
0				
0				
0				
0			0	0
22,714	22,714	0	0	0
22,714	22,714	0	0	
22,714	22,714	0	0	0
22,714	22,714	0	0	
15,359				
3,840				
147.89% 591.54%				
C0060				
22,714				
22,675				
0				
39				
45,833				
-13,033				

45,833

# 5.25.01.21 Solvency Capital Requirement - for undertakings on Standard Formula

		Gross solvency capital requirement	USP	Simplifications
		C0110	C0090	C0120
R0010	Market risk	3,802		
R0020	Counterparty default risk	674		
R0030	Life underwriting risk	12,365		
R0040	Health underwriting risk	2,126		
R0050	Non-life underwriting risk	0		
R0060	Diversification	-4,163		-
R0070	Intangible asset risk	0	USP Key For life underwriting	risk:
R0100	Basic Solvency Capital Requirement	14,805	1 - Increase in the am benefits 9 - None	ount of annuity
	Calculation of Solvency Capital Requirement	C0100	For health underwrit	
R0130	Operational risk	1,233	benefits	
R0140	Loss-absorbing capacity of technical provisions	-679	2 - Standard deviation premium risk	for NSLT health
R0150	Loss-absorbing capacity of deferred taxes			for NSLT health gross
R0160	Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	0	4 - Adjustment factor	for non-proportional
R0200	Solvency Capital Requirement excluding capital add-on	15,359	reinsurance 5 - Standard deviation	o for NSLT health
R0210	Capital add-ons already set	0	reserve risk	TO TOLI TERRIT
R0220	Solvency capital requirement	15,359	9 - None	
	Other information on SCR		For non-life underwr 4 - Adjustment factor	
R0400		0	6 - Standard deviation	for non-life
R0410		0	premium risk 7 - Standard deviation	for non-life gross
R0420	Total amount of Notional Solvency Capital Requirements for ring fenced funds	0	premium risk	
R0430	Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	0	8 - Standard deviation reserve risk	for non-tife
R0440	Diversification effects due to RFF nSCR aggregation for article 304	0	9 - None	
	Approach to tax rate	C0109		
R0590	Approach to tax rate  Approach based on average tax rate	0		
	Calculation of loss absorbing capacity of deferred taxes	LAC DT		
DOC 40	LAC DT	C0130		
R0650		0		
R0660		0		
R0670	LAC DT justified by reference to probable future taxable economic profit  LAC DT justified by carry back, current year	0		
R0680	LAC DT justified by carry back, future years	0		
KU690	Maximum LAC DT	0		

D0040	Linear formula component for non-life insurance and reinsurance obligations MCR <sub>NL</sub> Result	C0010		
K0010	mck <sub>lk</sub> result	U	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
			C0020	C0030
R0020	Medical expense insurance and proportional reinsurance			
R0030	Income protection insurance and proportional reinsurance			
R0040	Workers' compensation insurance and proportional reinsurance			
R0050	Motor vehicle liability insurance and proportional reinsurance			
R0060	Other motor insurance and proportional reinsurance			
R0070	Marine, aviation and transport insurance and proportional reinsurance			
R0080	Fire and other damage to property insurance and proportional reinsurance			
R0090	General liability insurance and proportional reinsurance			
R0100	Credit and suretyship insurance and proportional reinsurance			
R0110				
R0120	Assistance and proportional reinsurance			
R0130				
R0140	Non-proportional health reinsurance			
R0150				
R0160	Non-proportional marine, aviation and transport reinsurance			
R0170	Non-proportional property reinsurance			
	Linear formula component for life insurance and releguezance childrations	C0040		
posoo	Linear formula component for life insurance and reinsurance obligations MCR. Result	818		
KUZUU	MCRL RESULT	010		
			Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
			reinsurance/SPV) best estimate and TP	reinsurance/SPV) total
R0210	Obligations with profit participation - guaranteed benefits		reinsurance/SPV) best estimate and TP calculated as a whole	reinsurance/SPV) total capital at risk
	Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits		reinsurance/SPV) best estimate and TP calculated as a whole	reinsurance/SPV) total capital at risk
R0220			reinsurance/SPV) best estimate and TP calculated as a whole	reinsurance/SPV) total capital at risk
R0220 R0230	Obligations with profit participation - future discretionary benefits		reinsurance/SPV) best estimate and TP calculated as a whole C0050  22,344 4,008	reinsurance/SPV) total capital at risk
R0220 R0230 R0240	Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations		reinsurance/SPV) best estimate and TP calculated as a whole C0050  22,344  4,008  1,381	reinsurance/SPV) total capital at risk C0060
R0220 R0230 R0240 R0250	Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations Overall MCR calculation	C0070	reinsurance/SPV) best estimate and TP calculated as a whole C0050  22,344  4,008  1,381	reinsurance/SPV) total capital at risk
R0220 R0230 R0240 R0250	Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations	C0070 818	reinsurance/SPV) best estimate and TP calculated as a whole C0050  22,344  4,008  1,381	reinsurance/SPV) total capital at risk C0060
R0220 R0230 R0240 R0250	Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations Overall MCR calculation Linear MCR	818 15,359	reinsurance/SPV) best estimate and TP calculated as a whole C0050  22,344  4,008  1,381	reinsurance/SPV) total capital at risk C0060
R0220 R0230 R0240 R0250 R0300 R0310 R0320	Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations  Overall MCR calculation Linear MCR SCR MCR cap	818 15,359 6,912	reinsurance/SPV) best estimate and TP calculated as a whole C0050  22,344  4,008  1,381	reinsurance/SPV) total capital at risk C0060
R0220 R0230 R0240 R0250 R0300 R0310 R0320	Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations  Overall MCR calculation Linear MCR SCR	818 15,359	reinsurance/SPV) best estimate and TP calculated as a whole C0050  22,344  4,008  1,381	reinsurance/SPV) total capital at risk C0060
R0220 R0230 R0240 R0250 R0300 R0310 R0320 R0330	Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations  Overall MCR calculation Linear MCR SCR MCR cap	818 15,359 6,912	reinsurance/SPV) best estimate and TP calculated as a whole C0050  22,344  4,008  1,381	reinsurance/SPV) tota capital at risk C0060
R0220 R0230 R0240 R0250 R0310 R0310 R0320 R0330 R0340	Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations  Overall MCR calculation Linear MCR SCR MCR cap MCR floor	818 15,359 6,912 3,840	reinsurance/SPV) best estimate and TP calculated as a whole C0050  22,344  4,008  1,381	reinsurance/SPV) tota capital at risk C0060

### **Validation**

National Deposit Friendly Society Limited (the 'Society')

Approval by the Board of Directors of the Solvency and Financial Condition Report

Financial period ended 31 December 2023.

We certify that:

- 1. The Solvency and Financial Condition Report ('SFCR') has been properly prepared in all material respects in accordance with the PRA Rulebook; and
- 2. We are satisfied that:
  - a. Throughout the financial year in question the Society has complied in all material respects with the requirements of the PRA Rulebook as applicable to the Society: and
  - b. It is reasonable to believe that, at the date of publication of the SFCR, the Society has continued so to comply, and will continue so to comply in future.

Approval by the Board of the SFCR and reporting templates

**Graham Singleton** 

Chief Executive Officer

For and on behalf of the Board

P.L. Sayll

Date: 5 April 2024